Taking It Back to Basics: Re-emphasizing the Role of Moisturization in Atopic Dermatitis

Overview

Journal J Clin Aesthet Dermatol

Date 2024 Mar 6

PMID 38444427

Authors

Raj Chovatiya

Affiliations

Soon will be listed here.

Abstract

Atopic dermatitis (AD) is a common, burdensome inflammatory skin disease. In recent years, multiple safe and effective monotherapy treatments directly targeting immune dysregulation in AD have been approved and integrated into clinical practice. Although the etiopathogenesis of AD is complex, it is widely recognized that alongside immune dysregulation, skin barrier disruption also plays an essential role in disease pathophysiology. For this reason, regular moisturization has been a foundational mainstay of therapy, consistently recommended by treatment guidelines regardless of disease severity or therapeutic approach. It is vital for healthcare providers to continuously educate patients and caregivers about the importance of optimizing skin barrier function by maintaining proper moisturization as part of their treatment plan and help them make data-driven decisions to navigate the wide array of available products.

References

Kemeny L, Varga E, Novak Z . Advances in phototherapy for psoriasis and atopic dermatitis. Expert Rev Clin Immunol. 2019; 15(11):1205-1214. DOI: 10.1080/1744666X.2020.1672537. View

Margolis D, Mitra N, Gochnauer H, Wubbenhorst B, DAndrea K, Kraya A . Uncommon Filaggrin Variants Are Associated with Persistent Atopic Dermatitis in African Americans. J Invest Dermatol. 2018; 138(7):1501-1506. PMC: 6272058. DOI: 10.1016/j.jid.2018.01.029. View

Niedzwiedz M, Skibinska M, Narbutt J, Lesiak A . Off-label medications in the treatment of hospitalized children with atopic dermatitis. Postepy Dermatol Alergol. 2023; 40(1):72-77. PMC: 9993195. DOI: 10.5114/ada.2022.119967. View

Flohr C . How we treat atopic dermatitis now and how that will change over the next 5 years. Br J Dermatol. 2023; 188(6):718-725. DOI: 10.1093/bjd/ljac116. View

Paller A, Siegfried E, Thaci D, Wollenberg A, Cork M, Arkwright P . Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020; 83(5):1282-1293. DOI: 10.1016/j.jaad.2020.06.054. View

Berdyshev E, Goleva E, Bissonnette R, Bronova I, Bronoff A, Richers B . Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. Allergy. 2022; 77(11):3388-3397. DOI: 10.1111/all.15432. View

Simpson E, Bieber T, Guttman-Yassky E, Beck L, Blauvelt A, Cork M . Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016; 375(24):2335-2348. DOI: 10.1056/NEJMoa1610020. View

Weber T, Samarin F, Babcock M, Filbry A, Rippke F . Steroid-Free Over-the-Counter Eczema Skin Care Formulations Reduce Risk of Flare, Prolong Time to Flare, and Reduce Eczema Symptoms in Pediatric Subjects With Atopic Dermatitis. J Drugs Dermatol. 2015; 14(5):478-85. View

Micali G, Paterno V, Cannarella R, Dinotta F, Lacarrubba F . Evidence-based treatment of atopic dermatitis with topical moisturizers. G Ital Dermatol Venereol. 2018; 153(3):396-402. DOI: 10.23736/S0392-0488.18.05898-4. View

10.

Hebert A, Rippke F, Weber T, Nicol N . Efficacy of Nonprescription Moisturizers for Atopic Dermatitis: An Updated Review of Clinical Evidence. Am J Clin Dermatol. 2020; 21(5):641-655. PMC: 7473959. DOI: 10.1007/s40257-020-00529-9. View

11.

Simpson E, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M . Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020; 396(10246):255-266. DOI: 10.1016/S0140-6736(20)30732-7. View

12.

Eichenfield L, Tom W, Chamlin S, Feldman S, Hanifin J, Simpson E . Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2013; 70(2):338-51. PMC: 4410183. DOI: 10.1016/j.jaad.2013.10.010. View

13.

Puar N, Chovatiya R, Paller A . New treatments in atopic dermatitis. Ann Allergy Asthma Immunol. 2020; 126(1):21-31. DOI: 10.1016/j.anai.2020.08.016. View

14.

Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour J . Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2020; 184(3):437-449. PMC: 7986411. DOI: 10.1111/bjd.19574. View

15.

Cork M, Danby S, Vasilopoulos Y, Hadgraft J, Lane M, Moustafa M . Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009; 129(8):1892-908. DOI: 10.1038/jid.2009.133. View

16.

Cerio R, Dohil M, Jeanine D, Magina S, Mahe E, Stratigos A . Mechanism of action and clinical benefits of colloidal oatmeal for dermatologic practice. J Drugs Dermatol. 2010; 9(9):1116-20. View

17.

Guttman-Yassky E, Teixeira H, Simpson E, Papp K, Pangan A, Blauvelt A . Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021; 397(10290):2151-2168. DOI: 10.1016/S0140-6736(21)00588-2. View

18.

Draelos Z . Modern moisturizer myths, misconceptions, and truths. Cutis. 2013; 91(6):308-14. View

19.

Chovatiya R . Atopic Dermatitis (Eczema). JAMA. 2023; 329(3):268. PMC: 10190158. DOI: 10.1001/jama.2022.21457. View

20.

Sidbury R, Tom W, Bergman J, Cooper K, Silverman R, Berger T . Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014; 71(6):1218-33. PMC: 4430554. DOI: 10.1016/j.jaad.2014.08.038. View